Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
20.96B
Market cap20.96B
Price-Earnings ratio
8.07
Price-Earnings ratio8.07
Dividend yield
—
Dividend yield—
Average volume
3.02M
Average volume3.02M
High today
$160.64
High today$160.64
Low today
$155.01
Low today$155.01
Open price
$159.02
Open price$159.02
Volume
2.05M
Volume2.05M
52 Week high
$479.79
52 Week high$479.79
52 Week low
$149.18
52 Week low$149.18

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $158.88. The company's market cap stands at 20.96B, with a P/E ratio of 8.07.

As of 2026-11-17, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $155.01 and $160.64. The current price stands at $158.88, placing the stock +2.5% above today's low and -1.1% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 2.05M, compared to an average daily volume of 3.02M.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $479.79 and a 52-week low of $149.18.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $479.79 and a 52-week low of $149.18.

ALNY News

TipRanks 13h
Alnylam price target lowered to $205 from $290 at Cantor Fitzgerald

Cantor Fitzgerald lowered the firm’s price target on Alnylam (ALNY) to $205 from $290 and keeps a Neutral rating on the shares. Alnylam has lost over $30B in ma...

Simply Wall St 1d
Did Alnylam Pharmaceuticals' 64% Drop Catch You Out? What Bears Saw - Simply Wall St

...

Did Alnylam Pharmaceuticals' 64% Drop Catch You Out? What Bears Saw - Simply Wall St
Simply Wall St 2d
Is Alnylam Pharmaceuticals Undervalued On Strong New AMVUTTRA Data?

Alnylam Pharmaceuticals (ALNY) has become a focus for many investors after new five-year AMVUTTRA data presented at the American Heart Association Scientific Se...

Is Alnylam Pharmaceuticals Undervalued On Strong New AMVUTTRA Data?

Analyst ratings

67%

of 30 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

More ALNY News

Simply Wall St 6d
Alnylam Pharmaceuticals Is Up 5.4% What’s Changed After Five Year Drug Data

Alnylam Pharmaceuticals reported new five year HELIOS-B data showing continuous AMVUTTRA treatment was associated with lower all-cause mortality and recurrent c...

Alnylam Pharmaceuticals Is Up 5.4% What’s Changed After Five Year Drug Data

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.